Seeking Alpha

Reopened for trade, ArQule (ARQL) falls 21% after the testing failure of its key drug,...

Reopened for trade, ArQule (ARQL) falls 21% after the testing failure of its key drug, tivantnib. The rest of the company's pipeline.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|